| Atrial fibrillation is one of the commonest sustained disorder of cardiac rhythm. It's incidence is second only to the ventrical premature beats. It has potential risk of causing arteriaes, especially cerebral arteries to form thrombo-embolism(cerebral arterial thrombosis), which is the main factor of causing death and mutilation in atrial fibrillation patients.Warfarin is the only effective and efficient drug that decreases the complication of embolism for the time being. These concepts have been realized and received by more and more doctors. But many doctors are lack of the experienments about the application of Warfarin, they are not familiar with the way how to monitor the action of Warfarin, and how to adjust the dosage of Warfarin. We carried out the serious clinical observation and tests, and compare the effect and distinction of Warfarin of different anticoatulation intensities and aspirin preventing thrombo-embolism in non-valular atrial fibrillation patients in order to try to establish themry foundation of suitable anticoagulative intensities of Warfarin. Objective: By measuring regular two molecul marks(D-Dimer,β-platelet globulin )and clinical indexes such as trans-breast ultrasonic cardiogram in different groups of patients. We try to find out the effect of prophylactic anticoagulation therapy of cerebral arterial thrombosis and systemic circulation embolism in non-valvular atrial fibrillation patients, and try to find out suitable anticoagulation intensities which is maked with international standard odds(INR).Methods: We choose sixty non-valvular atrial fibrillation patients, aged from fifty to eighty. It's average is 61±5 years old, They are divided into three groups randomly: stardard-dose Warfarin group(INR2.1—2.5, A group), low-dose Warfarin group(INR1.6—2.0), aspirin group(200mg/dd, C group), and every group has 20 patients. The general datas(sex,age,progress,dangerous factors and so on)of three groups A,B,C are not significant different(detail in chart 1—4).Warfarin comes from Aolian pharmaceutical factory in Finland. The first dosage is 3mg/d, then adjust dosage according to INR. After take orally Warfarin, we must measure INR on the 3rd,7th,15 th day, then adjust the dosage of Warfarin. We will withdrawl 3ml elbow venous blood in the morning when the patients don't have breastfast. Then we centrifugate(2000r×10min)those blood, and segregate the serum, and conserve in the –20 degree refigerabo in ordor to measure those. DD andβ-platelet globulin all adopt enzyme-linked immuno-sorbent assay to measure.The test kits come from Shanghai. The data are designated by ±S. The measurement data among groups adopt analysis of variance. The tests within groups adopt paired t-test. The comparison of the regularity of the variance of count data adopts Chi-square test. P>0.05 shows that the data have no significant variation. P<0.05 shows that the data have significant variation. P<0.01 shows that the data have strongly significant variation.Results:1.The comparison of the concentration change of D-Dimer in group A,B,C before and after the treatment: The concentrations of D-Dimer in all the three groups are significantly lower than those before the treatment(P<0.01). After the therapy, the D-Dimer concentration in group A is significantly lower than group B and C. 2.The comparison of the concentrations ofβ-platelet globulin in group A,B,C before and after the treatment: The concentrations ofβ-platelet globulin in all the three groups are significantly lower than those before the treatment(P<0.01). After the treatment, theβ-platelet globulin concentration in group A is significantly lower than group B and C. 3.The comparison of the incidence of thrombo-embolism in the three groups after the treatment. The lowest incidence of thrombo-embolism is group A after the treatment. But there is not significant variance among the groups. Perhaps the result is caused by the shortage of the cases.Conclusion: The experiment shows that the incidence of thromb...
|
PDF Full Text Request